In recent trading session, Turnstone Biologics Corp (NASDAQ:TSBX) saw 1.38 million shares changing hands at last check today with its beta currently measuring 1.26. Company’s recent per share price level of $0.35 trading at $0.02 or 5.33% at last check today assigns it a market valuation of $8.10M. That most recent trading price of TSBX’s stock is at a discount of -757.14% from its 52-week high price of $3.00 and is indicating a premium of 17.14% from its 52-week low price of $0.29. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 79990.0 shares which gives us an average trading volume of 263.34K if we extend that period to 3-months.
For Turnstone Biologics Corp (TSBX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Turnstone Biologics Corp (NASDAQ:TSBX) trade information
Upright in the green today for gaining 5.33%, in the last five days TSBX remained trading in the red while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $0.35 price level, adding 10.23% to its value on the day. Turnstone Biologics Corp’s shares saw a change of -87.89% in year-to-date performance and have moved -6.59% in past 5-day. Turnstone Biologics Corp (NASDAQ:TSBX) showed a performance of 1.33% in past 30-days. Number of shares sold short was 0.43 million shares which calculate 0.78 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 0.5 to the stock, which implies a rise of 30.0% to its recent value today. Analysts have been projecting 0.5 as a low price target for the stock while placing it at a high target of 0.5. It follows that stock’s current price would drop -42.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -42.86% for stock’s current value.
Turnstone Biologics Corp (NASDAQ:TSBX)’s Major holders
Insiders are in possession of 7.70% of company’s total shares while institution are holding 52.82 percent of that, with stock having share float percentage of 57.23%. Investors also watch the number of corporate investors in a company very closely, which is 52.82% institutions for Turnstone Biologics Corp that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at TSBX for having 3.1 million shares of worth $8.12 million. And as of 2024-06-30, it was holding 13.453 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 1.14 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.9278 of outstanding shares, having a total worth of $2.97 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 431.16 shares of worth $0.15 million or 1.86% of the total outstanding shares. The later fund manager was in possession of 85.69 shares on Apr 30, 2025 , making its stake of worth around $30213.0 in the company or a holder of 0.37% of company’s stock.
